

**Academic Personnel Short Profile / Short CV**

<b>University:</b>	University of Nicosia
<b>Surname:</b>	Jovanović
<b>Name:</b>	Aleksandar
<b>Rank/Position:</b>	Professor
<b>Faculty:</b>	Medical School
<b>Department:</b>	Basic and Clinical Sciences
<b>Scientific Domain:</b>	Clinical Pharmacology

**Academic qualifications**

<b>Qualification</b>	<b>Year</b>	<b>Awarding Institution</b>	<b>Department</b>
Board Certification in Clinical Pharmacology	1996	University of Belgrade	Medicine-Clinical Pharmacology
PhD	1995	University of Belgrade	Medicine-Pharmacology
MD	1988	University of Belgrade	Medicine
Certificate in Medical Education	2001	University of Dundee	Medical Education

**Employment history in Academic Institutions/Research Centers**

<b>Period of employment</b>		<b>Employer</b>	<b>Location</b>	<b>Position</b>
<b>From</b>	<b>To</b>			
03/2018	Present	University of Nicosia	Nicosia	Professor
10/1999	02/2018	University of Dundee	Dundee	2006-2018 Professor 2005-2006 Reader 2003-2005 Senior Lecturer 1999-2003 Lecturer
12/1998	08/1999	Mayo Medical School	Rochester, MN	Instructor

**Key refereed journal papers, monographs, books, conference publications etc.**

Ref. Number	Year	Title	Other authors	Journal and Publisher / Conference	Vol.	Pages
1	2019	Isosteviol prevents the development of isoprenaline-induced myocardial hypertrophy.	Chen Y, Beng H, Su H, Han F, Fan Z, Lv N, Tan W.	<i>International Journal of Molecular Medicine</i>	<b>44</b>	1932-1942
2	2019	Pyrazinamide may possess cardioprotective properties.	Sinha S, Du Q, Jovanovic S, Sukhodub A.	<i>Journal of Antibiotics</i>	<b>72</b>	714-717
3	2018	Cardioprotective signalling: Past, present and future.		<i>European Journal of Pharmacology</i>	<b>833</b>	314-319
4	2017	Exposure to 15% oxygen <i>in vivo</i> up-regulates cardioprotective SUR2A without affecting ERK1/2 and Akt: A crucial role for AMPK.	Mohammed Abdul KS, Jovanovic S.	<i>Journal of Cellular and Molecular Medicine</i>	<b>21</b>	1342-1350
5	2016	A spontaneous increase in intracellular Ca <sup>2+</sup> in metaphase II human oocytes <i>in vitro</i> can be prevented by drugs targeting ATP-sensitive K <sup>+</sup> channels.	Fernandes G, Dasai N, Kozlova N, Mojadidi A, Gall M, Drew E, Barratt E, Madamidola O, Brown S, Milne A, Martins Da Silva S, Whalley K, Barratt C.	<i>Human Reproduction</i>	<b>31</b>	287-297
6	2015	Mild hypoxia <i>in vivo</i> regulates cardioprotective SUR2A: A role for Akt and LDH.	Mohammed Abdul KS, Jovanovic S, Du Q, Sukhodub A	<i>Biochimica et Biophysica Acta</i>	<b>1852</b>	709-719
7	2010	Role of the WNK-activated SPAK kinase in regulating blood pressure.	Rafiqi FH, Zuber AM, Glover M, Richardson C, Fleming S, Jovanovic S, O'Shaughnessy KM, Alessi DR.	<i>EMBO Molecular Medicine</i>	<b>2</b>	63-75

8	2006	Overexpression of SUR2A generates a cardiac phenotype resistant to ischaemia.	Du Q, Jovanovic S, Clelland A, Sukhodub A, Budas GR, Phelan K, Murray-Tait V, Malone L, Jovanovic A.	<i>FASEB Journal</i>	<b>20</b>	1131-1141
9	2002	M-LDH serves as a sarcolemmal K <sub>ATP</sub> channel subunit essential for cell protection against ischemia.	Crawford RM, Budas GR, Jovanovic S, Ranki HJ, Wilson TJ, Davies AM.	<i>EMBO Journal</i>	<b>21</b>	3936-3948
10	2000	Mechanical unloading versus neurohumoral stimulation on myocardial structure and endocrine function in vivo.	Lisy O, Redfield MM, Jovanovic S, Jougasaki M, Leskinen H, Terzic A, Burnett J C Jr.	<i>Circulation</i>	<b>102</b>	338-343

Research Projects				
Ref. Number	Date	Title	Funded by	Project Role
1	2016-2018	IES-SUR2B-mediated cardioprotection	British Heart Foundation	Principal Investigator
2	2013-2016	Regulation of subsarcolemmal ATP by sarcolemmal K <sub>ATP</sub> channels: is it important for cardioprotection?"	British Heart Foundation	Principal Investigator
3	2010-2013	A novel genetic approach to investigate the mechanism by which mutations in AMPK cause glycogen storage disease and Wolff-Parkinson-White syndrome	British Heart Foundation	Principal Investigator
4	2009-2013	mTOR as a regulator of airway and vascular development in the fetal lung	Wellcome Trust	Co-Investigator
5	2009-2011	Increased expression of SUR2A as a strategy to counteract ageing-induced decrease in cardiac output and physical endurance	British Heart Foundation	Principal Investigator
6	2008-2011	Overexpression of SUR2A as a strategy to counteract ageing-induced increase in myocardial susceptibility to ischaemia	British Heart Foundation	Principal Investigator

7	2006-2010	Non-channel aspects of sarcolemmal $K_{ATP}$ channels and cardioprotection	British Heart Foundation	Principal Investigator
8	2006-2010	Sonoptics: exploiting ultrasound and laser sciences for generic non-invasive therapies	Engineering and Physical Sciences Research Council	Co-Investigator
9	2005-2008	The involvement of M-LDH physically associated with sarcolemmal $K_{ATP}$ channel subunits in cardioprotection	Medical Research Council	Principal Investigator
10	2005-2008	A link between sarcolemmal ATP-sensitive $K^+$ ( $K_{ATP}$ ) channels and AMP-activated protein kinase (AMPK) in mediating cardioprotective signalling	British Heart Foundation	Principal Investigator

### Academic Consulting Services and/or Participation in Councils / Boards/ Editorial Committees

Ref. Number	Period	Organization	Title of Position or Service	Key Activities
1	2017-present	Elsevier	Editor of European Journal of Pharmacology	Editing and selecting scientific manuscripts for publication
2	2015-2016	Academy of Finland's Grants Evaluation Panel	Member	Grants assessing
3	2009-present	Various Publishers	Member of Editorial Boards of <u>6</u> Biomedical Journals	Scientific manuscripts assessment
4	1995-present	Various Publishers	Reviewer for <u>41</u> international biomedical journals	Reviewing scientific manuscripts
5	2001-present	Various funding bodies	Reviewer for <u>10</u> international Funding Bodies	Reviewing Grants Proposal

### Awards / International Recognition

Ref. Number	Date	Title	Awarded by:
1	11/2018	Honorary Professor	St George's University of London
2	03/2003	Fellow	Higher Education Academy
3	01/2001	Fellow	Institute for Learning and Teaching in Higher Education
4	10/1999	Honorary Visiting Scientist	Mayo Clinic and Foundation
5	07/1997	Merck Sharp & Dohme Award in Clinical Pharmacology	Merck Company Foundation

6	03/1997	Presidential Award	American Society for Clinical Pharmacology and Therapeutics
7	03/2003	Fellow	Higher Education Academy

Other Achievements			
Ref. Number	Date	Title	Key Activities:
1	07/2009	"SUR2A Therapy" (PCT/GB2009/001705) and (WO/2010/004283)	Patent
2	01/2015	"Biomarker for Vascular Endothelial Function" UK patent application no. 1213705.5.	Patent